Furthermore, suppression of ezrin function using shRNA and dominant negative ezrin mutants abrogates invasion, early metastatic survival, as well as lung metastases in osteosarcoma, rhabdomyosarcoma [9,19], and breast carcinoma [20-22] cell lines. The gene discussed is EZR; the disease is breast carcinoma.